The Trial to Assess Chelation Therapy 2 (TACT2): Rationale and Design.

[1]  P. Landrigan,et al.  Pollution and the Heart. , 2021, The New England journal of medicine.

[2]  Amanda J. Fairchild,et al.  A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement. , 2021, JAMA.

[3]  G. Lamas,et al.  Lead and Cadmium as Cardiovascular Risk Factors: The Burden of Proof Has Been Met , 2021, Journal of the American Heart Association.

[4]  G. Lamas,et al.  Low-level metal contamination and chelation in cardiovascular disease - a ripe area for toxicology research. , 2021, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  Deepak L. Bhatt,et al.  Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[6]  G. Lamas,et al.  Urinary Metal Levels after Repeated Edetate Disodium Infusions: Preliminary Findings , 2020, International journal of environmental research and public health.

[7]  Effect of high‐dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT) , 2018, American heart journal.

[8]  G. Lamas,et al.  Enhanced vasculotoxic metal excretion in post‐myocardial infarction patients following a single edetate disodium‐based infusion , 2017, Environmental research.

[9]  G. Lamas,et al.  Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. , 2016, Journal of the American College of Cardiology.

[10]  K. Anstrom,et al.  Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. , 2015, Journal of the American College of Cardiology.

[11]  G. Lamas,et al.  The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT) , 2014, Circulation. Cardiovascular quality and outcomes.

[12]  G. Lamas,et al.  Oral High-Dose Multivitamins and Minerals After Myocardial Infarction , 2013, Annals of Internal Medicine.

[13]  L. Appel,et al.  Enough Is Enough: Stop Wasting Money on Vitamin and Mineral Supplements , 2013, Annals of Internal Medicine.

[14]  B. Howard,et al.  Cadmium Exposure and Incident Cardiovascular Disease , 2013, Epidemiology.

[15]  G. Lamas,et al.  Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. , 2013, JAMA.

[16]  G. Lamas,et al.  Design of the Trial to Assess Chelation Therapy (TACT). , 2012, American heart journal.

[17]  G. Lamas,et al.  Quality of life after late invasive therapy for occluded arteries. , 2009, The New England journal of medicine.

[18]  K. Anstrom,et al.  Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. , 2009, American heart journal.

[19]  A. Tsiatis,et al.  Empirical estimation of life expectancy from large clinical trials: Use of left‐truncated, right‐censored survival analysis methodology , 2008, Statistics in medicine.

[20]  K. Anstrom,et al.  Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. , 2008, American heart journal.

[21]  N. Bryden,et al.  EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc , 2001, Biological Trace Element Research.

[22]  A. Tsiatis,et al.  Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) , 2006, Circulation.

[23]  S. Thompson,et al.  Multiple regression of cost data: use of generalised linear models , 2004, Journal of health services research & policy.

[24]  Anastasios A. Tsiatis,et al.  Estimating medical costs with censored data , 2000 .

[25]  A A Tsiatis,et al.  Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. , 2000, Circulation.

[26]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[27]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[28]  L. J. Wei,et al.  The Robust Inference for the Cox Proportional Hazards Model , 1989 .

[29]  R. Prentice,et al.  Commentary on Andersen and Gill's "Cox's Regression Model for Counting Processes: A Large Sample Study" , 1982 .

[30]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[31]  Committee for proprietary medicinal products (CPMP) points to consider on adjustment for baseline covariates , 2022 .